T-cell acute lymphoblastic leukemia (T-ALL) is a highly proliferative hematologic malignancy
that results from the transformation of immature T-cell progenitors. Aberrant cell growth and …

Acute lymphoblastic leukemia (ALL) is the most successful paradigm of how risk-adapted
therapy and detailed understanding of the genetic alterations driving leukemogenesis and …

Genetic alterations that activate NOTCH1 signaling and T cell transcription factors, coupled
with inactivation of the INK4/ARF tumor suppressors, are hallmarks of T-lineage acute …

X-linked SCID (SCID-X1) is amenable to correction by gene therapy using conventional
gammaretroviral vectors. Here, we describe the occurrence of clonal T cell acute …

T-cell acute lymphoblastic leukemias (T-ALL) are immature lymphoid tumors localizing in the
bone marrow, mediastinum, central nervous system, and lymphoid organs. They account for …

The most common pediatric malignancy is acute lymphoblastic leukemia (ALL), of which T‐
cell ALL (T‐ALL) comprises 10–15% of cases. T‐ALL arises in the thymus from an immature …

Activating mutations in NOTCH1 are the most prominent genetic abnormality in T-cell acute
Lymphoblastic Leukemia (T-ALL) and inhibition of NOTCH1 signaling with γ-secretase …

The identification of activating mutations in NOTCH1 in over 50% of T-cell acute
lymphoblastic leukemias (T-ALL) has generated major interest in the elucidation of the …

Cyclin C was cloned as a growth-promoting G1 cyclin, and was also shown to regulate gene
transcription. Here we report that in vivo cyclin C acts as a haploinsufficient tumour …

Gain-of-function NOTCH1 mutations are found in 50%–70% of human T cell acute
lymphoblastic leukemia/lymphoma (T-ALL) cases. Gain-of-function NOTCH1 alleles that …